UNM RAINFOREST INNOVATIONS (20240277678). METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY simplified abstract
METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY
Organization Name
Inventor(s)
Eric R. Prossnitz of Albuquerque NM (US)
Geetanjali Sharma of Albuquerque NM (US)
Matthias Barton of Zurich (CH)
Matthias R. Meyer of Stallikon (CH)
METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY - A simplified explanation of the abstract
This abstract first appeared for US patent application 20240277678 titled 'METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY
The current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). These compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of NOX and NOX-associated reactive oxygen species (ROS).
- Compounds that modulate the effects of GPR30/GPER for treating obesity and diabetes
- Compounds that can be used as agonists and/or antagonists of the estrogen receptor
- Modulation of the expression/upregulation of NOX and NOX-associated reactive oxygen species (ROS)
- Treatment of disease states and conditions resulting from excessive formation of reactive oxygen species
- Potential therapeutic applications in the fields of molecular biology and pharmacology
Potential Applications: - Treatment of obesity and diabetes - Management of disease states related to excessive reactive oxygen species - Pharmacological interventions in molecular biology research
Problems Solved: - Addressing obesity and diabetes through targeted modulation of GPR30/GPER - Managing disease states associated with reactive oxygen species overproduction - Providing novel therapeutic approaches in molecular biology and pharmacology
Benefits: - Improved treatment options for obesity and diabetes - Targeted interventions for diseases linked to reactive oxygen species - Advancements in molecular biology and pharmacology research
Commercial Applications: Title: Novel Compounds for Treating Obesity and Diabetes: Market Implications Description: The technology offers potential commercial uses in pharmaceuticals for obesity and diabetes treatment, as well as in research for disease states related to reactive oxygen species.
Questions about the technology: 1. How do compounds modulating GPR30/GPER offer new treatment possibilities for obesity and diabetes? 2. What are the potential implications of targeting NOX and NOX-associated ROS in disease management?
Original Abstract Submitted
the current invention is in the field of molecular biology/pharmacology and provides methods of using compounds that modulate the effects of gpr30/gper for treating obesity and diabetes (preferably agonists) as well as disease states and/or conditions that result from excessive formation of reactive oxygen species (preferably antagonists). these compounds may function as agonists and/or antagonists of the disclosed estrogen receptor and/or modulate the expression/upregulation of nox and nox-associated reactive oxygen species (ros).
